TREFOIL FAMILY FACTOR PROTEINS AND USES THEREOF
The invention provides for methods for treating an inflammatory disease of the digestive system in a subject by administering a trefoil family molecule. The invention provides for methods for treating a digestive system cancer in a subject by administering a trefoil family molecule. The invention provides for methods for cell proliferation in a subject by administering a trefoil family molecule.
1 - 51 . (canceled)
52 . A method of treating a disease or condition in a subject comprising administering to the subject a TFF1 molecule, a TFF2 molecule, a TFF3 molecule, or a combination thereof, wherein the treatment is selected from the group consisting of treating a digestive system cancer, decreasing myeloid-derived suppressor cell proliferation, decreasing tumor growth, and treating dysplasia of the digestive system.
53 . The method of claim 52 , wherein the TFF1 molecule, TFF2 molecule, or TFF3 molecule is a nucleic acid.
54 . The method of claim 53 , wherein the nucleic acid is delivered as a viral vector.
55 . The method of claim 53 , wherein the nucleic acid comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4 and SEQ ID NO: 6.
56 . The method of claim 52 , wherein the digestive system cancer is selected from the group consisting of small intestine cancer, large intestine cancer, colon cancer, rectal cancer, and anal cancer.
57 . The method of claim 52 , wherein the myeloid-derived suppressor cell is a tumor associated myeloid-derived suppressor cell.
58 . The method of claim 52 , wherein the myeloid-derived suppressor cell expresses a MDSC-specific surface marker.
59 . The method of claim 52 , wherein the myeloid derived suppressor cell does not express a MDSC-specific surface marker.
60 . The method of claim 58 , wherein the MDSC-specific surface marker is selected from the group consisting of (1) Grl1, CD11b, or a combination thereof; and (2) CD14, CD15, CD33, or a combination thereof.
61 . The method of claim 59 , wherein the MDSC-specific surface marker is HLA-DR.
62 . A kit for use for the method of claim 52 , the kit comprising a TFF1 molecule, a TFF2 molecule, a TFF3 molecule, or a combination thereof, and instructions of use.
63 . A method of determining the presence of, or predisposition to, a cancer of the digestive system in a sample from a subject, the method comprising:
(a) detecting the presence, absence or reduction of a TFF1 molecule, TFF2 molecule, or a TFF3 molecule in the sample, wherein absence, or reduction of the molecule indicates the presence of, or predisposition to, a cancer of the digestive system.
64 . The method of claim 63 , further comprising (b) administering a TFF1 molecule, a TFF2 molecule, a TFF3 molecule, or a combination thereof to the subject where a TFF1 molecule, a TFF2 molecule, or a TFF3 molecule was not detected.
65 . The method of claim 63 , further comprising incubating the sample with an agent that binds a TFF1 molecule, a TFF2 molecule, or a TFF3 molecule, or fragment thereof.
66 . The method of claim 65 , wherein the agent is an antibody to a TFF1 molecule, a TFF2 molecule, or a TFF3 molecule.
67 . The method of claim 63 , wherein the digestive system cancer is selected from the group consisting of small intestine cancer, large intestine cancer, colon cancer, rectal cancer, and anal cancer.
68 . The method of claim 63 , wherein the TFF1 molecule, TFF2 molecule, or TFF3 molecule is a nucleic acid.
69 . The method of claim 68 , wherein the nucleic acid is delivered as a viral vector.
70 . A diagnostic kit for determining the presence of, or predisposition to, a cancer of the digestive system, the kit comprising an agent that binds to a TFF1 molecule, a TFF2 molecule, or a TFF3 molecule, and instructions for use.
71 . The kit of claim 70 , wherein the agent is an antibody to a TFF1 molecule, a TFF2 molecule, or a TFF3 molecule.